Document is current
Any future updates will be listed below
-
Authors
Kappel, Kalli https://orcid.org/0000-0002-2129-199X
Strebinger, Daniel https://orcid.org/0000-0001-8732-6414
Edmonds, KeHuan K. https://orcid.org/0000-0002-7317-2669
Chau-Duy-Tam VO, Samuel https://orcid.org/0000-0001-6020-4716
Vockley, Christopher M.
Biswas, Tridib https://orcid.org/0000-0003-3539-4751
Farhi, Samouil L. https://orcid.org/0000-0003-1359-4568
Macrae, Rhiannon https://orcid.org/0000-0002-7850-9056
Zhang, Feng https://orcid.org/0000-0003-0178-7995
Regev, Aviv https://orcid.org/0000-0003-3293-3158
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (Hanna H. Gray Fellows Program)
Schmidt Science Fellows, in partnership with the Rhodes Trust
Swiss National Science Foundation
Helen Hay Whitney Foundation Postdoctoral Fellowship
Klarman Cell Observatory
- License Information
-
More Information
Article History
Received: 9 September 2024
Accepted: 16 May 2025
First Online: 16 June 2025
Competing interests
: A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until 31 August 2020 was a scientific advisory board member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. Since 1 August 2020, A.R. has been an employee of Genentech, a member of the Roche Group, with equity in Roche. F.Z. is a scientific advisor and cofounder of Beam Therapeutics, Pairwise Plants, Arbor Biotechnologies, Aera Therapeutics and Moonwalk Biosciences. F.Z. is also a scientific advisor for Octant. All other authors declare no competing interests.
